Human granulosa tumor cell (GCT) lines (KGN and COV434) were utilized to establish the combinatorial effects of TRAIL treatment and a proteasome inhibitor on cell viability, in vitro. TRAIL induced a slight, but consistent, decrease in viability for both cell lines, and pharmacologic inhibition of proteasome activity, using Z-LLF-CHO (Z-LLF), synergistically enhanced TRAIL-induced loss of viability. This enhanced sensitization was associated with the up-regulation of a TRAIL receptor, DR5, and pro-apoptotic Bax. Targeted reduction of p53 expression revealed that the ability of Z-LLF to enhance DR5 and Bax expression occurs independent of p53 activity. These studies underscore the potential to develop targeted treatments for GCTs using established cell lines.

Inhibiting proteasome activity enhances TRAIL-induced cell death in human granulosa tumor cells, offering potential for targeted treatments using established cell lines.

Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death.

Key Takeaway: Inhibiting proteasome activity enhances TRAIL-induced cell death in human granulosa tumor cells, offering potential for targeted treatments using established cell lines.